Trial Profile
A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada in Antiretroviral Therapy naive HIV-1 Infected Patients (VERxVE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Nevirapine
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms VERxVE
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Nov 2017 Results of PK sub-study published in the HIV Clinical Trials
- 27 Mar 2012 Planned number of patients changed from 1033 to 1250 as reported by European Clinical Trials Database.
- 18 Jan 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.